Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure
Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure
复制标题
DOI:
10.1016/j.clinbiochem.2010.02.001
复制
发表时间:
2010-05-01
影响因子:
2.8
通讯作者:
Gardiner, Peter
中科院分区:
文献类型:
--
作者:
Christenson, Robert H.;Duh, Show-Hong;Gardiner, Peter
Background: Galectin-3 is a carbohydrate binding protein that plays many important regulatory roles in inflammation, immunity and cancer. Recent studies indicate that galectin-3 is a mediator of heart failure development and progression. Development of an improved assay for galectin-3 measurement was necessary for appropriate clinical assessment. Key analytical performance characteristics, the reference distribution and association of galectin-3 levels with clinical outcome in heart failure patients are defined.Methods: A two-site ELISA test was examined for measurement matrix, imprecision, limits of blank, detection, and quantitation, as well as linearity, high-dose hook effect, storage stability, cross-reactivity with nine similar compounds, interference with 22 common medications and icterus, lipemia and hemolysis, all in accordance with CLSI guidance. Also the effects of human anti-mouse antibodies and rheumatoid factor on recovery of galectin-3 were investigated. The reference interval was determined for 1092 ostensibly healthy individuals. The association of galectin-3 concentrations with an outcome of mortality was examined in a preliminary analysis of 129 acute decompensated heart failure patients.Results: Galectin-3 results were equivalent when measured in serum or EDTA plasma. Imprecision studies demonstrated that the total CV was